Ground News

See every side of every news story

Pharmaceutical-technology.com image

News from Pharmaceutical-technology.com

See all of Pharmaceutical-technology.com’s headline news. Compare how the top news stories are covered by left-wing and right-wing news sources.

In total, 540 have been published by Pharmaceutical-technology.com which Ground News has aggregated in the past 3 months.

Ground News rates Pharmaceutical-technology.com’s media bias as . . Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check.

Pharmaceutical-technology.com’s factuality rating is Unknown. Ground News calculates this rating using a combination of the fact and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about Pharmaceutical-technology.com

Where is Pharmaceutical-technology.com located?Pharmaceutical-technology.com's Website

Media Bias Ratings

Do you diasgree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top Pharmaceutical-technology.com News

UN to continue Gaza vaccination campaign against polio

UN to continue Gaza vaccination campaign against polio

67% Right coverage: 6 sources

The UN World Health Organization (WHO) announced on Wednesday that the mass polio vaccination campaign in Gaza which began successfully last year, will continue in the coming days.See the Story

Pfizer to Discontinue Its Hemophilia B Gene Therapy

Pfizer to Discontinue Its Hemophilia B Gene Therapy

67% Center coverage: 3 sources

Fidanacogene elaparvovec was approved last year, and had a price of $3.5 million per doseSee the Story

Once high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy maker

Once high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy maker

100% Center coverage: 1 sources

Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday.See the Story

Breaking News Topics Related to Pharmaceutical-technology.com